APYX Stock Forecast: Apyx Medical Corp. Price Predictions for 2026-2027
The 6 Wall Street analysts covering Apyx Medical Corp. hold a median 12-month price target of $6 — +150.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 76 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Apyx Medical Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (92): Analysts have, on balance, been raising their forecasts.
Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
APYX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on APYX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +150.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | Maxim Group | Initiates | Buy | $6.00 |
| 13 July 2026 | HC Wainwright & Co. | Initiates | Buy | $7.00 |
| 11 Mar 2026 | BTIG | Upgrade | Buy | — |
| 11 Mar 2026 | Craig-Hallum | Maintains | Buy | — |
| 16 Dec 2025 | Roth Capital | Initiates | Buy | — |
| 12 Nov 2025 | Citizens | Upgrade | Market Outperform | — |
| 17 Oct 2024 | BTIG | Initiates | Neutral | — |
| 16 Sept 2024 | JMP Securities | Reiterates | Market Perform | — |
| 10 Nov 2023 | Stephens & Co. | Maintains | Overweight | — |
| 11 Aug 2023 | Piper Sandler | Maintains | Overweight | — |
| 14 July 2023 | Stephens & Co. | Initiates | Overweight | — |
| 15 June 2023 | Lake Street | Maintains | Buy | — |
| 24 May 2023 | JMP Securities | Reiterates | Market Perform | — |
| 12 May 2023 | Lake Street | Maintains | Buy | — |
| 8 Dec 2022 | Lake Street | Assumes | Buy | $5.00 |
| 12 Aug 2022 | Piper Sandler | Maintains | Overweight | — |
| 19 July 2022 | Lake Street | Maintains | Buy | — |
| 20 May 2022 | Lake Street | Initiates | Buy | — |
| 13 Aug 2021 | JMP Securities | Maintains | Market Outperform | — |
| 12 May 2020 | JMP Securities | Maintains | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for APYX.
This page is one stock. Monday covers all of them.
APYX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
APYX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Apyx Medical Corp. returned −40.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
APYX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.7×
- Price / book
- 10.5×
- EV / EBITDA
- —
Cheaper than 53% of US stocks
Cheaper than 7% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 63.9%
- Operating margin
- −5.5%
- Net margin
- −14.2%
Higher than 77% of US stocks
Higher than 29% of US stocks
Higher than 18% of US stocks
- Return on equity
- −102.5%
- Return on assets
- −3.4%
- Dividend yield
- —
Higher than 13% of US stocks
Higher than 35% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Apyx Medical Corp. has a market value of $101.1M and an enterprise value of $115.5M.
Revenue in the twelve months to 30 June 2026: $58.4M. The latest quarter grew 22.1% year on year.
Net income over the same four quarters: −$8.4M, a −14.4% net margin.
Diluted earnings per share, trailing twelve months: −$0.20.
Free cash flow in the twelve months to 30 June 2026: −$11.0M.
Apyx Medical Corp. employs 205 people — $285K of revenue per employee.
Data provided by Twelve Data
APYX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at APYX’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Apyx Medical Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about APYX
What is the APYX stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Apyx Medical Corp. have a median 12-month price target of $6, with estimates ranging from $6 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is APYX stock a buy right now?
Of the 6 analysts covering Apyx Medical Corp., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Apyx Medical Corp. 76 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank APYX?
As at 21 Nov 2026, Apyx Medical Corp. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).
Will APYX stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +150.0% from the last close, and Ticker Nerd's factor model ranks Apyx Medical Corp. 76 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the APYX stock forecast for 2030?
No analyst covering Apyx Medical Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APYX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $8 over the next 12 months.
How has APYX stock performed over the past year?
Apyx Medical Corp. returned -40.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Apyx Medical Corp. do?
Apyx Medical Corporation is a medical technology company that develops, manufactures, and markets advanced energy-based surgical products for cosmetic and general surgical use. The company’s portfolio includes helium plasma technology systems, handheld devices, generators, and related accessories designed to support precise tissue cutting, coagulation, and ablation in open and minimally invasive procedures.
About Apyx Medical Corp.
Apyx Medical Corporation is a medical technology company that develops, manufactures, and markets advanced energy-based surgical products for cosmetic and general surgical use. The company’s portfolio includes helium plasma technology systems, handheld devices, generators, and related accessories designed to support precise tissue cutting, coagulation, and ablation in open and minimally invasive procedures. Its products are used by physicians, surgery centers, hospitals, and other healthcare providers across surgical aesthetics and broader electrosurgical applications. Apyx Medical Corporation also serves original equipment manufacturing customers with engineered medical devices and components. Headquartered in Clearwater, Florida, Apyx Medical Corporation focuses on tools that combine energy delivery and surgical performance for modern operating environments.
CEO Mr. Charles D. Goodwin II · 205 employees · United States · https://apyxmedical.com